← Eichor
Study identifier: NCT02357654 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

GnRH for Luteal Support in IVF/ICSI/FET Cycles

Condition: Infertility  ·  Sponsor: University Reproductive Associates

PhasePhase 4
Planned participants350
Who can joinFemale, 18 Years to 40 Years
Healthy volunteersNo

About this study

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

This description comes directly from the study's public registry record.

Talk to the study team

Peter G McGovern, MD  ·  201-288-6330  ·  mcgovepg@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

University Reproductive AssociatesHasbrouck Heights, New Jersey, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02357654